Not losing weight on semaglutide?
US$ 28.46
glp 1 glucagon dual receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Machine learning designs new GCGR/GLP-1R
Description
It is notable that high spikes of blood insulin, (Hyperinsulinemia), initiates inflammation, which over times causes atherosclerosis and its sequela cardiovascular heart disease (CHD)
In addition, these medicines stimulate the pancreas to produce insulin, allowing the body to convert ingested food into energy and reduce the amount of glucose in the bloodstream
Nausea rates in retatrutide trials reached approximately 45% at the maximum dose, compared to roughly 31% for tirzepatide
That is a meaningful gap
doi: 10.1056/NEJM199503093321001
